ZVSA (ZyVersa Therapeutics) Scaled Net Operating Assets : 0.35 (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ZyVersa Therapeutics's operating assets for the quarter that ended in Sep. 2024 was $19.30 Mil. ZyVersa Therapeutics's operating liabilities for the quarter that ended in Sep. 2024 was $12.40 Mil. ZyVersa Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was $19.47 Mil. Therefore, ZyVersa Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.35.

ZyVersa Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for ZyVersa Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZyVersa Therapeutics Scaled Net Operating Assets Chart

ZyVersa Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-7.17

-5.36

83.66

0.07

ZyVersa Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial										0.57	0.24	0.42	0.39	0.36

Competitive Comparison of ZyVersa Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, ZyVersa Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZyVersa Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's Scaled Net Operating Assets falls into.

ZyVersa Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ZyVersa Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(18.976	-	11.031)	/	118.506
=	0.07

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	22.114	-	3.138
=	18.976

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	11.04	-	0	-	0.009
=	11.031

ZyVersa Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(19.301	-	12.397)	/	19.47
=	0.35

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	19.424	-	0.123
=	19.301

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	12.397	-	0	-	0
=	12.397

ZyVersa Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

ZyVersa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326

Website

https://www.zyversa.com

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Executives

Pablo A. Guzman	officer: Chief Medical Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover	director, officer: Chief Executive Officer	108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr.	officer: Chief Scientific Officer	C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe	officer: Chief Financial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere	officer: Chief Commercial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park	director	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd.	10 percent owner	4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones	director, officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor	director, officer: Chief Executive Officer	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp.	10 percent owner	88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880